drugset / Trial / NCT04485702
Phase 1 Bioavailability Study of MELT-100 (Midazolam and Ketamine Sublingual) and IV Midazolam or Ketamine
RandomizedCrossoverSingle-blindOther
Summary
Comparative Bioavailability study testing MELT-100 (midazolam and ketamine sublingual tablet) and IV midazolam or ketamine in healthy volunteers
Timeline
- Start
- 2020-07-20
- Primary completion
- 2020-08-29
- Completion
- 2020-08-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ketamine | Small molecule | 6 mg | Intravenous |
| Comparator | Ketamine | Small molecule | 25 mg | Intravenous |
| Comparator | Midazolam | Small molecule | 2 mg | Intravenous |
| Comparator | Midazolam | Small molecule | 3 mg | Intravenous |
Indications
No indication recorded.